Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined effects of genetic and non-genetic risk factors affect response to ranibizumab in exudative age-related macular degeneration.

Acta ophthalmologica - 1 Sept 2015

Piermarocchi Stefano, Miotto Stefania, Colavito Davide, Leon Alberta, Segato Tatiana

Abstract excerpt

PURPOSE: To investigate whether genetic and non-genetic risk factors influence 12-month response to ranibizumab treatment for exudative age-related macular degeneration (AMD). METHODS: A cohort of 94 Caucasian patients with unilateral exudative AMD received intravitreal ranibizumab. After a three-injection loading phase, a PRN regimen was followed. Patients were genotyped for three single-nucleotide...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Complement C3

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Complement Factor H

Share to Intravitreal Injections

Share to Pharmacogenetics

Share to Vascular Endothelial Growth Factor A

Share to Visual Acuity

Share to Wet Macular Degeneration

Source

Identifiers

PMID: 25402348
DOI: 10.1111/aos.12587

Genes

CFH
ARMS2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined effects of genetic and non-genetic risk factors affect response to ranibizumab in exudative age-related macular degeneration.PMID 25402348Read ↗

Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab.Semantic proximity Read ↗

Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration.Semantic proximity Read ↗

Involvement of genetic factors in the response to a variable-dosing ranibizumab treatment regimen for age-related macular degeneration.Semantic proximity Read ↗

The influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis).Semantic proximity Read ↗

Predicting non-response to ranibizumab in patients with neovascular age-related macular degeneration.Semantic proximity Read ↗

Genetic variants in three genes and smoking show strong associations with susceptibility to exudative age-related macular degeneration in a Chinese population.Semantic proximity Read ↗

Evaluation of clinical and genetic indicators for the early response to intravitreal ranibizumab in exudative age-related macular degeneration.Semantic proximity Read ↗

Genetic Risk Evaluation in Wet Age-Related Macular Degeneration Treatment Response.Semantic proximity Read ↗

Genetic influences on the outcome of anti-vascular endothelial growth factor treatment in neovascular age-related macular degeneration.Semantic proximity Read ↗

Influence of Genetic Polymorphisms on the Short-Term Response to Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration.Semantic proximity Read ↗

Nongenetic risk factors for neovascular age-related macular degeneration.Semantic proximity Read ↗

Analysis of Genetic and Environmental Risk Factors and Their Interactions in Korean Patients with Age-Related Macular DegenerationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.